Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nutcracker Therapeutics Inc.
Headquarters: Emeryville, CA, United States of America
Website: https://www.nutcrackerx.com/...
Year Founded: 2018
Status: Private
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Feb 21, 2024
Management Tracks
Papa succeeds Miller as Emergent’s CEO
Plus: Paratus names Heah as CEO and updates from Jazz, Arvinas, KaliVir, Celcuity, QuidelOrtho, Turnstone and PhRMA
BioCentury | Jan 10, 2024
Management Tracks
Mark Alles at the helm at Torl
Plus: new CSO at Nutcracker, and updates from
BioCentury | Nov 15, 2023
Management Tracks
Rivus appoints Smith as chair and hires Schott as CMO
Plus: Noema and K36 hire CMOs and more from Myricx, Outlook and IMIDomics
BioCentury | Mar 9, 2023
Management Tracks
Biogen taps Dorsa to succeed Papadopoulos as chair
Plus: new chair at Venatorx, and updates from VarmX and Nutcracker
BioCentury | Oct 28, 2022
Emerging Company Profile
Nutcracker: RNA design, delivery and manufacturing under one roof
Leveraging an Arch-led $167 million series C round, Nutcracker’s RNA-based therapy for HPV-driven cancers is heading to the clinic
BioCentury | Sep 12, 2022
Management Tracks
Biden names Wegrzyn to lead ARPA-H
Plus bluebird’s Cole resigns as CFO, and updates from Cellics, Scorpion, Day One and more
BioCentury | Jun 22, 2022
Management Tracks
New COO, CBO at Nutcracker
Plus Guindo rejoins Merck to lead marketing of human health business, and updates from Arcellx, Angiex, Congenica and more
BioCentury | Mar 15, 2022
Finance
March 14 Quick Takes: Arch refills Nutcracker with $167M series C
Plus Ascendis meets in hypoparathyroidism and updates from BridgeBio, AZ, Sanofi, Pfizer and more
Items per page:
1 - 10 of 10